[1]
|
Safety implications of combined antiretroviral and anti-tuberculosis drugs
Expert Opinion on Drug Safety,
2020
DOI:10.1080/14740338.2020.1694901
|
|
|
[2]
|
L-T4 Therapy in the Presence of Pharmacological Interferents
Frontiers in Endocrinology,
2020
DOI:10.3389/fendo.2020.607446
|
|
|
[3]
|
Hypothyroidism associated with therapy for multi‐drug‐resistant tuberculosis in Australia
Internal Medicine Journal,
2019
DOI:10.1111/imj.14085
|
|
|
[4]
|
Operational research within a Global Fund supported tuberculosis project in India: why, how and its contribution towards change in policy and practice
Global Health Action,
2018
DOI:10.1080/16549716.2018.1445467
|
|
|
[5]
|
Global epidemiology of hyperthyroidism and hypothyroidism
Nature Reviews Endocrinology,
2018
DOI:10.1038/nrendo.2018.18
|
|
|
[6]
|
Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea
Medicine,
2017
DOI:10.1097/MD.0000000000007482
|
|
|
[7]
|
Tuberculosis and Nontuberculous Mycobacterial Infections
2017
DOI:10.1128/9781555819866.ch30
|
|
|